GLP-1 Drugs Show Promise for Sarcopenic Obesity But Carry Real Muscle-Loss Risk

Sarcopenic obesity is a clinically distinct and increasingly prevalent subtype of obesity defined by the simultaneous presence of reduced skeletal muscle mass, strength, or function alongside excess adiposity. It is estimated to affect approximately 28.3% of adults over age 60. This condition is particularly dangerous because the two components — sarcopenia and obesity — amplify each other's harmful effects. Excess fat drives chronic low-grade inflammation that degrades muscle tissue, while reduced muscle impairs metabolism and physical function, increasing fall risk, disability, and mortality. Aging compounds the problem through anabolic resistance, declining anabolic hormones, and reduced physical activity. This review, published in the American Diabetes Association's journal Diabetes, addresses the urgent clinical question of whether the new generation of incretin-based weight loss drugs can safely and effectively treat sarcopenic obesity in older adults.

The authors review the evidence for GLP-1 receptor agonists (GLP-1RAs) — principally liraglutide and semaglutide — as well as the dual gastric inhibitory polypeptide/GLP-1 receptor agonist (GIP/GLP-1RA) tirzepatide. In landmark trials conducted predominantly in younger adults, semaglutide (STEP trials) achieved roughly 15% total body weight loss, while tirzepatide (SURMOUNT trials) achieved up to 20–22% weight reduction. Both classes of drugs have also demonstrated improvements in physical function measures, cardiovascular outcomes, and quality of life. However, a consistent and concerning finding across these trials is that approximately 25–39% of total weight lost consists of lean mass, not just fat. In older adults already experiencing age-related muscle decline, this lean mass loss could tip the balance from therapeutic benefit to functional harm.

The review critically examines the limited data on GLP-1RAs in older adults specifically. The STEP 2 and SURMOUNT-2 trials included participants with type 2 diabetes, but few trials systematically enrolled older adults with confirmed sarcopenia or measured muscle-specific outcomes rigorously. Available subgroup analyses suggest that physical function improvements do occur, but whether these improvements persist when accounting for the degree of muscle mass lost is unclear. The authors note that no trial to date has specifically recruited an older adult population with clinically defined sarcopenic obesity as its primary population and used validated sarcopenia endpoints — a critical evidence gap.

Given this gap, Chen and Batsis propose a pragmatic clinical framework for using incretin therapies in this population. They recommend beginning with careful patient identification using validated criteria — such as grip strength, gait speed, or appendicular lean mass indexed to height — before initiating therapy. Monitoring during treatment should include serial assessments of muscle mass and function, not just body weight, with dose adjustments or discontinuation considered if significant lean mass loss is detected. The authors emphasize that concurrent resistance exercise and adequate dietary protein intake (targeting ≥1.2 g/kg/day) are essential adjuncts to mitigate muscle catabolism during drug-induced caloric restriction.

Looking ahead, the review highlights two emerging drug classes as potentially transformative for sarcopenic obesity. Activin type II receptor antibodies (e.g., bimagrumab) have shown striking results in early trials, with one study demonstrating fat mass reduction of approximately 20.5% alongside lean mass increase of 3.6% over 48 weeks, a profile directly opposite to the muscle-losing effects of GLP-1RAs. Selective androgen receptor modulators (SARMs) represent another avenue for selectively building muscle without the systemic androgenic effects of testosterone. The authors also invoke geroscience — the science of targeting fundamental aging mechanisms such as cellular senescence, mitochondrial dysfunction, and chronic inflammation — as a framework for eventually personalizing treatments based on biological rather than chronological age. These approaches remain investigational but represent the frontier of sarcopenic obesity therapeutics.